---
schema_version: "secwatch.filing_event.v1"
accession: "0000200406-23-000073"
form_type: "8-K"
ticker: "JNJ"
cik: "0000200406"
company_name: "JOHNSON & JOHNSON"
filed_at: "2023-07-20T23:59:59+00:00"
generated_at: "2026-06-13T05:51:04.656145+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# JNJ Q2 sales up 6.3% to $25.5B; raises FY guidance; Kenvue spin-off via exchange offer

## Summary
- Q2 2023 sales $25.53B (+6.3%); operational sales growth 7.5% excluding COVID-19 vaccine 8.9%.
- GAAP diluted EPS $1.96 (+8.9%); adjusted diluted EPS $2.80 (+8.1%).
- FY 2023 adjusted operational sales ex-COVID vaccine and adjusted operational EPS guidance midpoints raised.
- Board authorizes Kenvue share split-off via exchange offer as next step in separation.

## SEC filing metadata
- accession: 0000200406-23-000073
- form_type: 8-K
- ticker: JNJ
- cik: 0000200406
- company_name: JOHNSON & JOHNSON
- filed_at: 2023-07-20T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/200406/000020040623000073/0000200406-23-000073-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/200406/000020040623000073/jnj-20230720.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000200406-23-000073
- JSON: https://secwatch.observer/filing/0000200406-23-000073.json
- Plain text: https://secwatch.observer/filing/0000200406-23-000073.txt

## Key facts
- Earnings Releases
  JOHNSON & JOHNSON reported second quarter ended July 2, 2023 results: revenue $25.5 Billion, net income $5,144, EPS $1.96. Guidance raised.
  - Period: second quarter ended July 2, 2023
  - Revenue: $25.5 Billion
  - Net income: $5,144
  - EPS: $1.96
  - Guidance: raised
  - Result: reported results
  source text: the second quarter ended July 2, 2023. --- EX-99.1 (EX-99.1) --- JOHNSON & JOHNSON REPORTS 2023 SECOND-QUARTER RESULTS: • 2023 Second-Quarter reported sales growth of 6.3% to $25.5 Billion with operational growth of 7.5%* and adjusted operational growth of 6.2%*. Operational growth excluding COVID-19 Vaccine of 8.9%* • Earnings per share (EPS) of $1.96 increasing
  evidence_url: https://www.sec.gov/Archives/edgar/data/200406/000020040623000073/0000200406-23-000073-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.